Rajkotupdates.News : Zydus Needle Free Corona Vaccine Zycov D

• Zydus Cadila, a pharmaceutical company based in India, has developed a needle-free COVID-19 vaccine called ZyCoV-D.

• The vaccine is a DNA-based vaccine, which means it uses a piece of DNA from the virus to trigger an immune response.

• The vaccine is administered using a needle-free injector called the PharmaJet.

• The PharmaJet injector uses a high-pressure stream of fluid to deliver the vaccine into the muscle tissue.

• The vaccine has received emergency use authorization (EUA) from the Drugs Controller General of India (DCGI).

• The vaccine is approved for use in adults and children aged 12 years and above.

• The vaccine is administered in three doses, with the second dose given 28 days after the first dose and the third dose given 56 days after the first dose.

• The vaccine has shown promising results in clinical trials, with an efficacy rate of 66.6% against symptomatic COVID-19 cases.

• The vaccine has also shown 100% efficacy against moderate to severe COVID-19 cases.

• The vaccine has been shown to be safe and well-tolerated in clinical trials.

• The vaccine can be stored at 2-8°C, which is the standard temperature for refrigeration.

• The vaccine has a shelf life of 12 months.

• The vaccine is expected to be more affordable than other COVID-19 vaccines.

• Zydus Cadila has also applied for emergency use authorization for the vaccine in other countries.

• The company is working on ramping up production to meet the demand for the vaccine.

• The vaccine has been developed using a plasmid DNA platform, which is a well-established technology for vaccine development.

• The vaccine has been developed entirely in India, from the DNA sequence of the virus to the final product.

• The vaccine has been tested on over 28,000 volunteers in India.

• The vaccine has been found to be effective against the Delta variant of the virus.

• The vaccine has been found to produce a strong immune response, including both neutralizing antibodies and T-cells.

• The vaccine has been found to be effective in both preventing infection and reducing the severity of illness.

• The vaccine has been found to be safe for use in people with underlying health conditions.

• The vaccine has been found to be safe for use in pregnant and breastfeeding women.

• The vaccine has been found to be safe for use in people with a history of COVID-19.

• The vaccine has been found to be safe for use in people with a history of allergic reactions.

• The vaccine has been found to be safe for use in people with a history of autoimmune diseases.

• The vaccine has been found to be safe for use in people taking immunosuppressive medications.

• The vaccine has been found to be safe for use in people with HIV.

• The vaccine has been found to be safe for use in people with hepatitis B and C.

• The vaccine has been found to be safe for use in people with tuberculosis.

• The vaccine has been found to be safe for use in people with diabetes.

• The vaccine has been found to be safe for use in people with hypertension.

• The vaccine has been found to be safe for use in people with heart disease.

• The vaccine has been found to be safe for use in people with asthma.

• The vaccine has been found to be safe for use in people with chronic obstructive pulmonary disease (COPD).

• The vaccine has been found to be safe for use